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ABSTRACT* 
Objective: To identify how ‘elderly’ patients are defined 
and considered within Australian clinical guidelines for the 
use of pharmacotherapy. 
Method: Guidelines pertaining to the use of 
pharmacotherapy, focusing on conditions described in 
National Health Priority Areas, were identified using 
databases (Medline, Google Scholar) and organisation 
websites (Department of Health and Ageing, National 
Heart Foundation, National Health and Medical Research 
Council). Guidelines were reviewed and qualitatively 
analysed to identify any references or definitions of 
‘elderly’ persons.  
Results: Among the 20 guidelines reviewed, 3 defined 
‘elderly’ by chronological age (i.e., years since birth) while 
the remaining 17 guidelines did not define ‘elderly’ in any 
way. All 20 guidelines used the term ‘elderly’, whilst some 
guidelines provided age (chronological)-based dosage 
recommendations suggesting an ageist or generalist 
approach in their representation of ‘elderly’, for which 
rationale was seldom provided. Thematic analysis of the 
statements revealed five key themes regarding how 
‘elderly’ was considered within the guidelines, broadly 
describing ‘elderly’ persons as being frail and with altered 
pharmacology. Some guidelines also highlighted the 
limited evidence base to direct clinical decision-making. A 
continuum of perceptions of ageing also emerged out of 
the identified themes. 
Conclusion: Clinical practice guidelines currently do not 
adequately define ‘elderly’ persons and provide limited 
guidance on how to apply treatment recommendations to 
older persons. The representation of ‘elderly’ in guidelines 
needs to be less based on chronological age or generic 
definitions focusing more on establishing a direct link 
between an individual patient’s characteristics and the 
pharmacology of their prescribed medication. Clinical 
guidelines that do not offer any practical descriptions of 
the features of ageing that are specifically related to the 
use of pharmacotherapy, or how to assess these in 
individual patients, render decision-making challenging. 
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INTRODUCTION 
Globally, the population is ageing and the World 
Health Organisation (WHO) predicts that, by 2050, 
the population aged 60 years or more will double, 
whilst those aged 80 years or more will number 400 
million persons.1 This extension of the lifespan is 
looked upon as a triumph of medical advances, 
stemming from access to better treatments as well 
as a focus on preventive therapies; the use of 
pharmacotherapy is the key contributor to this.2 
Overall, people are using more medication than 
ever before and, whilst the use of pharmacotherapy 
has helped people live longer, its use is more 
complicated and risk-prone in older persons.3 
Herein lays the conundrum: pharmacotherapy has 
facilitated the ageing of the population, however, in 
the process, has created a population of persons 
that needs complex polypharmacy to manage their 
chronic health conditions3, but who also are at-risk 
of age-associated physiological, functional, and 
cognitive changes that increase the risk of adverse 
drug effects.4 
Inappropriate prescribing is often observed in older 
persons, with reports of both over-treatment5 and 
under-treatment6, rendering this population 
vulnerable to adverse clinical outcomes. Often, at 
the core of this inappropriate prescribing, is 
decision-making based on chronological age, which 
has sometimes been referred to as ‘ageism’ in the 
use of pharmacotherapy.7 Decision-making based 
on chronological age has been associated with the 
under-treatment of acute myocardial infarction6, 
congestive heart failure8, and atrial fibrillation.9 
While there is no doubt that health care 
professionals possess the skills to make 
individualised treatment decisions, there are ‘hot 
spots’ in practice where decision-making is 
particularly challenging and which needs some 
support. The evidence-base specifically highlights 
the issues of potential age-biases in prescribing, 
and this is reinforced by emotive discussions taking 
place in various practice settings identifying the 
experiences of practitioners and patients alike.10,11 
One classic example of this is in atrial fibrillation  
treatment; patients aged 80 years or more have 
been found to be five times less likely to receive 
warfarin compared to those aged less than 80 
years.9 
Ageing, an inevitable process, is commonly 
measured by chronological age and, as a 
convention, a person aged 65 years or more is often 
referred to as ‘elderly’.12,13 However, the ageing 
process is not uniform across the population due to 
differences in genetics, lifestyle, and overall 
health.14 Thus, chronological age fails to address 
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the heterogeneity observed among the ‘elderly’, 
particularly in regard to their pharmacotherapy 
needs where  pharmacokinetic and 
pharmacodynamic factors necessitate 
individualisation of regimens.14 However, there are 
no concrete definitions of ‘elderly’ that appropriately 
characterise this patient population; in using the 
generic terms ‘elderly’ and ‘older persons’ (even 
within this manuscript) there may be variable 
interpretations of the type of patients that is being 
referred to, and this is problematic when decision-
making specifically refers to these. These issues 
have never been more relevant to clinical practice, 
given the increasing emphasis on patient-centred 
care.15 Although, much attention has been paid to 
developing models and tools which help to 
individualise therapy (e.g., pharmacometrics16 and 
physiology-based pharmacokinetic (PBPK) 
modelling)17, seldom do they account for the diverse 
range of age-associated factors that influence 
decision-making in older persons. Moreover, these 
tools often include age as a determining parameter, 
with limited ability to tailor therapy to the needs of 
individual patients according to their unique 
attributes. For instance, one pharmacometric model 
defining the relationship between warfarin dose and 
the international normalised ratio has been based 
on genetic variations and chronological age only, 
without consideration of other key patient 
characteristics (e.g., comorbidities, polypharmacy, 
cognitive and functional impairments).18 Features of 
ageing must be appropriately considered within any 
strategy or tool (including clinical practice 
guidelines) focused on the individualisation of 
therapy.  
Clinical practice guidelines are ‘systematically 
developed statements to assist practitioner and 
patient decisions about appropriate health care for 
specific clinical circumstances’.19,20 A systematic 
review of clinicians’ attitudes towards clinical 
guidelines has found that 70% of the clinicians 
agree that guidelines are an important source of 
information. However, 30% criticised these 
guidelines for their limited applicability to individual 
patients.21 Thus, it is important to understand what 
limits the value of these guidelines in actual 
practice. The aim of this study was to explore how 
Australian clinical practice guidelines define an 
‘elderly’ patient, to what extent treatment 
recommendations are made specifically using these 
terms, and how they consider age-related 
parameters in the use of pharmacotherapy.  
 
METHODS  
Figure 1 describes the search strategy, data 
extraction, and search results. A structured review 
of clinical practice guidelines relating to the use of 
pharmacotherapy in Australia was undertaken, 
specifically identifying within each guideline: 
• Any specific definition of being ‘elderly’ 
(quantitative or qualitative definitions) 
• Pharmacokinetic and pharmacodynamic 
considerations while defining ‘elderly’ 
• Any age-specific consideration mentioned in the 
guidelines while making treatment 
recommendations 
The focus was specifically on clinical conditions 
mentioned as National Health Priority Areas (NHPA) 
which include arthritis, asthma, cancer, 
cardiovascular health, diabetes, dementia, mental 
health, and obesity, accounting for 72.8% of the 
total disease and injury burden in Australia.22 In 
Australia, the development of clinical practice 
guidelines is primarily overseen by the National 
Health and Medical Research Council (NHMRC), 
and/or specific professional organisations and 
societies specialising in particular areas (e.g. 
National Heart Foundation, National Stroke 
Foundation). These clinical practice guidelines are 
principally directed toward those clinicians and 
practitioners who are involved in therapeutic 
decision-making, including prescribers and 
treatment reviewers. 
Guidelines were sourced from an online repository 
(Clinical Practice Guidelines Portal- an initiative of 
the NHMRC)23 that was specifically developed to 
provide ready access to clinical guidelines via a 
single entry point. A search of the repository was 
undertaken to identify those guidelines addressing 
NHPAs, using key words relating to 
disease/condition names. Other key websites were 
additionally searched, including the Department of 
Health and Ageing, the National Heart Foundation 
of Australia, and NHMRC, as well as online 
databases, Google Scholar and Medline. Only 
current guidelines that were available in their 
entirety were selected for review, excluding those 
listed as rescinded. In total, 28 guidelines were 
initially identified, of which 8 were excluded from 
further review: 5 guidelines were listed as 
rescinded, and 3 guidelines were in fact only 
summaries of original guidelines. The remaining 20 
guidelines were then reviewed in regard to their 
consideration of older persons in treatment 
recommendations.  
To qualitatively analyse any descriptors of ‘elderly’, 
thematic analysis24 was applied to statements 
mentioning age related terms such as ‘elderly’ or 
“older”. To ensure the reliability of the analysis 
(thematic coding and interpretation), the extracted 
statements were independently reviewed by both 
researchers. The themes were independently 
derived, before a joint discussion to ensure a 
consensus was reached. Once the core themes had 




Overall, 20 guidelines were reviewed (Table 1). Of 
these, 3 guidelines defined being ‘elderly’ using 
chronological age; two guidelines defined ‘elderly’ 
by chronological age of 65 years or more and one 
guideline used the chronological age of 75 years or 
more. The remaining 17 guidelines did not define 
‘elderly’ by any specific measure.  
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None of the 20 guidelines purposefully emphasised 
altered drug pharmacology in older persons to 
distinguish how the use of the pharmacotherapy 
might differ in the ‘elderly’. However, the guidelines 
did include statements about specific 
recommendations, cautionary statements, referral 
procedures, diagnostic, and emergency care for 
‘elderly’ patients.  Five key themes emerged from 
the qualitative analysis of these statements, 
outlining how ‘elderly’ patients were variably 
A search was made for Australian 
Guidelines for conditions mentioned as 
National Health Priority Areas 




 Clinical Practice Guidelines portal 
 Department of Health and Ageing 
 Heart Foundation of Australia 
 National Health and Medical Research Council 
(NHMRC)
Guidelines studied for any definition of ‘elderly’




Three guidelines defined 
‘elderly’ using chronological age 
Seventeen guidelines did not 
define ‘elderly’ by any 
measure  
Key findingsTotal 20 guidelines were studied 
1x diabetes mellitus, neuropathic pain, respiratory health, obesity 
2x for vascular disorders and mental health 
3x musculoskeletal condition and cancer 
6x cardiovascular condition 
Theme 1: Age as a 
surrogate to 
comorbidity 
Theme 2: Altered drug pharmacology 
Theme 3: Limited 
evidence base
Theme 4: Old age, a contraindication to 
treatment




increased need to 

















‘elderly’. Risk and 
poor outcomes 
better predicted 
Continuum of perceptions about ageing
Key themes
17 guidelines sourced from Clinical Practice Guidelines portal 
2 Guidelines sourced from the NHMRC website 
1 guideline sourced from google scholar 
 Figure 1. Search strategy, data extraction, and search results
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considered within practice guidelines. The elicited 
core themes were explored for their relationship to 
each other, and the continuum of perceptions about 
the different levels of understanding about ‘ageing’ 
and its application in decision-making was mapped: 
awareness, acknowledgement, isolation, fear, and 
evolution (Figure 1). The key themes were: 
• Age as a surrogate to comorbidity (Awareness) 
• Recognition of issues related to altered drug 
pharmacology in elderly patients 
(Acknowledgement, Isolation) 
• Limited evidence base to define 
recommendations for older patients (Isolation) 
• Old age is associated with restrictions to the use 
of pharmacotherapy (Isolation, Fear) 
• Features of frailty may underpin treatment 
recommendations (Evolution)  
Age as a surrogate to comorbidity (Awareness) 
In four guidelines, the statements assumed that 
older persons had multiple co-morbidities and were 
at-risk of imminent death, almost treating the term 
‘elderly’ as a surrogate for comorbidity and 
expected ‘end of life’. Indeed, several guidelines 
acknowledged that the risk or prevalence of some 
diseases was higher in older persons, and therefore 
there was a need to treat more older persons, 
although none specifically described the 
considerations for using the therapies in this patient 
population. 
“In most affluent populations, including much 
of Australia, ARF (Acute Rheumatic Fever) is 
now rare, and RHD (Rheumatic Heart 
Disease) occurs predominantly in the 
elderly”.25 
As the majority of cancer patients are elderly, 
and as the incidence of VTE (Venous 
Thromboembolism) increases dramatically in 
patients aged greater than 55 years, most if 
not all cancer patients admitted to the hospital 
will fall into a high risk for subsequent VTE”.26 
“It is well established that VLUs (Venous Leg 
Ulcers) occur more often in older adults.27 
“It is therefore evident that for the foreseeable 
future we will continue to need to care for a 
significant number of older men with 
metastatic disease”.28 
Recognition of issues related to altered drug 
pharmacology in elderly patients 
(Acknowledgement, Isolation) 
In less than half of the guidelines (n=8), some 
statements stated the need to adjust drug doses in 
the elderly to reduce the risk of adverse drug 
outcomes. The underpinning link to the 
pharmacology of the therapy may be obvious to 
most clinicians, although none of the guidelines 
purposefully described the specific pharmacokinetic 
and pharmacodynamic considerations. 
“GPs should apply caution when using 
traditional NSAIDs and COX-2 NSAIDs in 
view of the known side effects, especially in 
the elderly, and those on concomitant 
medications. Careful monitoring of blood 
pressure and renal function is indicated in 
older people and others at risk when using 
these agents”.29 
“GPs should commence opioids at low 
starting dose with slow titration dose, 
particularly in people at increased risk of 
adverse effects, such as the elderly, and 
closely monitor patients for adverse effects”.29 
“The known cardiotoxic risk of tricyclic 
antidepressants (especially in overdose) 
needs to be balanced by the analgesic 
benefits for more elderly patients with 
stroke”.30 
“Addition of GI protective drugs to 
conventional NSAIDs can significantly reduce 
complications such as the incidence of GI 
Table 1. Definitions of ‘elderly’ extracted from clinical guidelines 
Guideline Definition of ‘elderly’ Primary developer 
Type 2 Diabetes33 No Diabetes Australia The Royal Australian College of General Practitioners 
Hypertension32 No National Heart Foundation of Australia 
Osteoporosis41 No The Royal Australian College of General Practitioners 
Rheumatoid arthritis31 No The Royal Australian College of General Practitioners 
Schizophrenia  
and related disorders57 No The Royal Australian and New Zealand College of Psychiatrists 
Stroke30 Yes (≥65 years) National Stroke Foundation 
Osteoarthritis29 No The Royal Australian College of General Practitioners 
Chronic heart failure58 No National Heart Foundation 
Chronic Obstructive 
Pulmonary Disease40 No 
The Thoracic Society of Australia and New Zealand  
The Australian Lung Foundation 
Absolute cardiovascular 
disease risk37 No National Vascular Disease Prevention Alliance 
Rheumatic heart disease25 No Rheumatic Heart Disease Australia  
Breast cancer59 No iSource National Breast Cancer Centre 
Lung cancer35 Yes (≥75 years) The Australian Cancer Network 
Neuropathic Pain34 No The Western Australia Therapeutic Advisory Group 
Prostate cancer28 No The Australian Cancer Network 
Venous leg ulcers27 No The Australian Wound Management Association 
Venous thromboembolism26 No New South Wales Department of Health 
Overweight and obesity38 No National Health and Medical Research Council 
Coronary heart disease39 No National Heart Foundation of Australia 
Major Depressive Disorder36 Yes  (≥65 years) Australasian Society for Bipolar and Depressive Disorders 
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bleeding and is recommended for RA patients 
over 65 years of age”.31 
“Commence at the lowest possible dose (ACE 
inhibitors and Angiotensin II receptor 
antagonists) in elderly patients and those 
taking diuretics”.32 
“Lowest doses (of Amlodipine and Felodipine) 
are recommended, particularly in the 
elderly”.32 
“With sulphonylureas special care needs to be 
taken, especially in the elderly, not to 
precipitate hypoglycaemia”.33 
“Starting dose for pregablin is 75 mg bd (25-
50 mg in the elderly and frail) [34] 
“Care should always be taken with opioid 
doses in the elderly and in the use of 
morphine in patients with renal failure” [35] 
“More caution (with tricyclic antidepressants) 
is indicated in children and the elderly and at 
higher doses” [36] 
Limited evidence base to define 
recommendations for older patients (Isolation) 
The statements from only two guidelines implied or 
otherwise specifically stated that there was a limited 
evidence base for the use of pharmacotherapy in 
older persons, and therefore afforded no practical 
advice to assist clinical decision-making. 
“However not all clinical situations in which 
their (blood pressure and lipid-lowering 
agents) use may be considered have been 
covered by clinical trials, e.g. in the elderly”.37 
“There is insufficient data to evaluate the 
safety and efficacy of weight loss medication 
… in older adults”.38 
Old age is associated with restrictions to the 
use of pharmacotherapy (Isolation, Fear) 
A quarter of guidelines (n=5) included statements 
that indicated that the use of pharmacotherapy 
should be restricted in older persons, and in some 
cases a specific chronological age was cited. The 
rationale for these restrictions was seldom provided, 
suggestive of potentially age-biased 
recommendations, some of which related to 
perceived safety considerations whilst other relating 
to treatment efficacy. 
Recommendations based on perceived safety 
considerations:   
“Prazosin not recommended in the elderly or 
patients with autonomic symptoms or cardiac 
failure”.33 
 “For patients with ACS (acute coronary 
syndromes) who are undergoing stenting, 
Prasugrel 10mg/day can be used as an 
alternative to Clopidogrel for 12 to 15 months. 
Avoid prescribing Prasugrel in patients with 
an increased risk of bleeding: for example, 
patients with history of smoke/TIA,low body 
weight (<60 kg), and advanced age 
(>75years)”.39 
Recommendations relating to efficacy: 
“CEA (carotid endarterectomy) for 
asymptomatic carotid stenosis is more 
beneficial for men than women and for 
younger rather than older patients”.30 
“Pneumococcal vaccination is known to be 
highly effective in preventing invasive 
bacteraemic pneumococcal pneumonia, but 
may be less effective in elderly or 
immunosuppressed patient”.40 
Unlike the preceding examples highlighting 
restrictions for the use of therapy in older persons, 
one statement, in contrast, limited the use of a 
therapy to ‘older’ patients only (in preference to 
younger persons). 
“The use of thiazide diuretics as first line 
therapy (for hypertension) to be limited to 
older patients”.32 
Such statements reflect an underestimation of 
remaining life expectancy in those aged 65 or more, 
and suggest that it may be appropriate to accept the 
risks of therapy more so in older persons.   
Features of frailty may underpin treatment 
recommendations (Evolution) 
Although none of the guidelines specifically 
discussed or described frailty, four guidelines 
included statements that suggested a link between 
frailty and ageing. Some of the recommendations 
mentioned attributes of old age (such as cognitive 
impairment, physical status) which may affect 
medication use/management in the elderly. Broadly 
speaking, the statements here address the concept 
of frailty and its application to clinical decision-
making.  
Recommendations associated with prescribing: 
“Less (insulin dose) may be required in 
elderly, active, thin patients and more in the 
overweight and underactive”.33 
“Antihypertensive therapy should be initiated 
with caution in the very old or frail (patients 
with comorbid acute stroke condition)”.32 
“Calcium intake is often sub-optimal in the 
elderly (especially institutionalised 
patients)”.41 
Generalised statements: 
“Many older people already have limited 
mobility, and obesity is likely to aggravate the 
problem and increase the risk of further 
functional problem”.38 
“The effect of excess weight on comorbidities 
such as Type 2 diabetes also reduce the 
ability of older people to participate in social 
and physical activities”.38 
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DISCUSSION 
A key finding of this study is that contemporary 
clinical guidelines either did not define ‘elderly’ by 
any useful means (85%) and/or otherwise employed 
chronological age as a definition (15%). While two 
guidelines defined those aged 65 or beyond as 
‘elderly’, one guideline used 75 years as cut-off for 
its description of ‘elderly’. This variability in setting a 
‘cut-off’ chronological age while defining ‘elderly’ is 
another issue which impedes a uniform description 
of ‘elderly’. Similar trends in variably defining 
‘elderly’ have been observed in a range of disease-
specific clinical studies, for instance atrial 
fibrillation.42-44 
Any underpinning characterisations of the ‘elderly’ 
appear to be very generic, not evidence-based, and 
potentially biased. Although most guidelines 
apparently consider the ‘elderly’ population as a 
vulnerable population when it comes to using 
pharmacotherapy, few guidelines are suggestive of 
the relationship between frailty and ageing, or the 
relationship between actual physiological changes 
and the pharmacological handling of a drug. More 
importantly, none of the guidelines identified that 
ageing is a heterogeneous process and therefore 
treatment use must be based on an individual 
assessment of relevant parameters underpinning 
the risk versus benefit of therapy. 
Individualised pharmacotherapy begins with the 
realisation that vulnerability to a particular clinical 
condition, its course, and response to prescribed 
pharmacotherapy are dependent on multiple factors 
including ageing, gender, genetics, lifestyle, and 
social-cultural aspects.45 Based on these factors, 
differing significantly from person to person, patients 
can be stratified for treatment recommendations, 
supporting a patient-centre treatment approach. Any 
treatment recommendation presented by clinical 
guidelines that regard the ‘elderly to be a 
homogenous group of people may limit the clinical 
benefits of therapy.46 For instance, one of the 
guidelines reviewed in this study limited the use of 
thiazide diuretics (associated with elevated risk of 
diabetes) as first line therapy to older people only.32 
Few studies have systematically addressed the 
issue of chronological age-based descriptions of 
‘elderly’ in clinical settings; however a few have 
argued the need to review definition. Orimo et al.13 
considered that, given the improving health status 
and functional independence in older persons, 
changing cut-off age from 65 years to 75 years to 
define ‘elderly’. Similarly,  improvements in health, 
cognition, and functional abilities of those aged 70 
or more were observed in a longitudinal study 
supporting the need to change the cut-off age for 
defining ‘elderly’.47 However, some researchers 
have recommended other options for defining being 
‘old’, for example, the use of biological age.48,49 In 
the context of clinical guidelines, it is important to 
base treatment recommendations on an individual 
assessment of those specific factors known to affect 
the use of a particular medication and avoid using 
generic age-based approaches. Other guidelines 
(not relevant to pharmacotherapy) also highlight the 
requirement of such an approach.50 
Clinical practice guidelines are important tools, but 
are frequently criticised for their insensitivity towards 
the needs of, and/or their limited applicability to, the 
older patient population.51 The findings of this study 
support this, in that the reviewed guidelines failed to 
present a comprehensive or practical definition of 
‘elderly’ either in qualitative or quantitative terms. 
Chronological age-based definitions of ‘elderly’, as 
presented in three guidelines, provide no insight 
about the actual health status and unique needs of 
a patient. Thus, such recommendations have limited 
ability to assist health professionals in decision-
making. A patient’s unique characteristics such as: 
altered drug handling, physical/functional and 
cognitive function, extent of comorbidity, 
polypharmacy, social situation, and quality of life, 
should be considered in clinical guidelines. Current 
guidelines only allude to these issues at a surface-
level, without adequate definition and support, and a 
few continue to use relatively arbitrary definitions of 
ageing based on chronological age.  
As the continuum of perception of ‘ageing’ ranges 
from ‘awareness’ to ‘evolution’, there is an 
increasing focus on to assist clinicians in prescribing 
for the ‘elderly’. Tools such as STOPP and START 
criteria52, BEERS criteria53, as well as pharmacist-
led review services54,55 can assist in rationalising 
therapy. The concept of frailty is also emerging as a 
more reliable predictor of the heterogeneity that 
exists in this potentially vulnerable population.49 The 
frailty index might be operationalised to determine 
the biological age of a patient48, providing a 
longitudinal measure of health status in an 
individual which can subsequently be applied to 
guide decision-making.14 
The inclusion of only Australian guidelines is a 
potential limitation of this study. However, although 
Australian guidelines have often (historically) been 
derived from international ones, this is less common 
in contemporary practice.56 Whilst it is not expected 
that practice and guidelines differ substantially in 
Australia compared to comparable international 
settings, further research in this area is needed to 
confirm the full scope of the issues.  
This study highlights the existing gaps in 
understanding of ‘old’ age and the ‘elderly’ 
underpinning some potential age-biases in 
medication prescribing, and highlighting the limited 
extent to which current clinical practice guidelines 
address this. Although clinicians’ abilities are not in 
question here, it is apparent that clinical guidelines 
often do not provide enough guidance on how to 
translate recommendations to individual patients, 
particularly older persons. More attention needs to 
be paid to this within guidelines given that no other 
factor displays more inter-patient variability in its 
presentation than ‘age’.   
 
CONCLUSIONS 
Clinical practice guidelines currently do not 
adequately define ‘elderly’ persons and provide 
limited guidance on how to apply treatment 
recommendations to older persons. The 
representation of ‘elderly’ in guidelines needs to be 
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less based on chronological age or generic 
definitions focusing more on establishing a direct 
link between an individual patient’s characteristics 
and the pharmacology of their prescribed 
medication. Clinical guidelines that do not offer any 
practical descriptions of the features of ageing that 
are specifically related to the use of 
pharmacotherapy, or how to assess these in 
individual patients, render decision-making 
challenging. 
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DEFINIENDO ‘ANCIANO’ EN LAS GUÍAS DE 
PRÁCTICA CLÍNICA PARA FARMACOTERAPIA  
 
RESUMEN 
Objetivo: Identificar como se define a los ‘ancianos’ y se 
les considera en las guías clínicas para uso de 
farmacoterapia. 
Método: Usando bases de datos (Medline, Google 
Scholar) y páginas web de las organizaciones 
(Department of Health and Ageing, National Heart 
Foundation, National Health and Medical Research 
Council) se identificaron las guías relativas al uso de 
farmacoterapia centradas en problemas de salud. Se 
revisaron las guías y se analizaron cualitativamente para 
identificar referencias o definiciones de personas 
‘ancianas’. 
Resultados: entre las 20 guías revisadas, 3 definían 
‘anciano’ por la edad cronológica (i.e. años desde el 
nacimiento), mientras que las 17 guías restantes no 
definían ‘anciano’ de forma alguna. Las 20 guías usaban 
el término ‘anciano’, aunque algunas proporcionaban 
recomendaciones de dosificación basadas en la edad 
(cronológicas) sugiriendo un abordaje peyorativo o 
generalista en la representación del ‘anciano’, para lo que 
raras veces se proporcionaba una justificación. El análisis 
temático de las afirmaciones reveló cinco temas en 
relación a como el ‘anciano’ era considerado en las guías, 
describiendo en general al ‘anciano’ como personas 
frágiles con farmacología alterada. Algunas guías 
también remarcaban la evidencia limitada para la toma de 
decisiones clínicas. También emergía de los temas 
identificados una idea de continuo de la percepción de 
envejecimiento. 
Conclusión: Las guías de práctica clínica no definen 
adecuadamente a las personas ‘ancianas’ y proporcionan 
una limitada orientación sobre cómo proveer 
recomendaciones de tratamiento a personas mayores. La 
representación de ‘anciano’ en las guías necesita estar 
menos basada en la edad cronológica o definición 
genérica, centrándose más en establecer un vínculo 
directo entre las características de un paciente individual 
y la farmacología de la medicación prescrita. Las guías 
clínicas que no ofrecen ninguna descripción práctica de 
los hechos del envejecimiento que se relacionan 
específicamente con la farmacoterapia, o como evaluar a 
esos pacientes individuales, provocan una toma de 
decisiones arriesgada, 
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